• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转录共抑制因子 Runx1t1 对于 MYCN 驱动的神经母细胞瘤肿瘤发生是必需的。

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.

机构信息

Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, 2031, Australia.

School of Clinical Medicine, UNSW Sydney, Sydney, NSW, Australia.

出版信息

Nat Commun. 2024 Jul 11;15(1):5585. doi: 10.1038/s41467-024-49871-0.

DOI:10.1038/s41467-024-49871-0
PMID:38992040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11239676/
Abstract

MYCN oncogene amplification is frequently observed in aggressive childhood neuroblastoma. Using an unbiased large-scale mutagenesis screen in neuroblastoma-prone transgenic mice, we identify a single germline point mutation in the transcriptional corepressor Runx1t1, which abolishes MYCN-driven tumorigenesis. This loss-of-function mutation disrupts a highly conserved zinc finger domain within Runx1t1. Deletion of one Runx1t1 allele in an independent Runx1t1 knockout mouse model is also sufficient to prevent MYCN-driven neuroblastoma development, and reverse ganglia hyperplasia, a known pre-requisite for tumorigenesis. Silencing RUNX1T1 in human neuroblastoma cells decreases colony formation in vitro, and inhibits tumor growth in vivo. Moreover, RUNX1T1 knockdown inhibits the viability of PAX3-FOXO1 fusion-driven rhabdomyosarcoma and MYC-driven small cell lung cancer cells. Despite the role of Runx1t1 in MYCN-driven tumorigenesis neither gene directly regulates the other. We show RUNX1T1 forms part of a transcriptional LSD1-CoREST3-HDAC repressive complex recruited by HAND2 to enhancer regions to regulate chromatin accessibility and cell-fate pathway genes.

摘要

MYCN 癌基因扩增在侵袭性儿童神经母细胞瘤中经常观察到。使用神经母细胞瘤易感转基因小鼠中的无偏大规模诱变筛选,我们在转录共抑制因子 Runx1t1 中鉴定出一个单一的种系点突变,该突变消除了 MYCN 驱动的肿瘤发生。该功能丧失突变破坏了 Runx1t1 内高度保守的锌指结构域。在独立的 Runx1t1 敲除小鼠模型中,删除一个 Runx1t1 等位基因也足以防止 MYCN 驱动的神经母细胞瘤发生,并逆转神经节增生,这是肿瘤发生的已知先决条件。在人神经母细胞瘤细胞中沉默 RUNX1T1 可减少体外集落形成,并抑制体内肿瘤生长。此外,RUNX1T1 敲低抑制 PAX3-FOXO1 融合驱动的横纹肌肉瘤和 MYC 驱动的小细胞肺癌细胞的活力。尽管 Runx1t1 在 MYCN 驱动的肿瘤发生中起作用,但这两个基因都不会直接调节另一个基因。我们表明 RUNX1T1 是 HAND2 募集的转录 LSD1-CoREST3-HDAC 抑制复合物的一部分,该复合物募集到增强子区域以调节染色质可及性和细胞命运途径基因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/847eaf2f29a0/41467_2024_49871_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/5206d27d47d0/41467_2024_49871_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/b874c6141b5d/41467_2024_49871_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/2c4db120430b/41467_2024_49871_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/e4e72e639016/41467_2024_49871_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/bc4df5149897/41467_2024_49871_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/4943d3bc534a/41467_2024_49871_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/2eff491dbe82/41467_2024_49871_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/847eaf2f29a0/41467_2024_49871_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/5206d27d47d0/41467_2024_49871_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/b874c6141b5d/41467_2024_49871_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/2c4db120430b/41467_2024_49871_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/e4e72e639016/41467_2024_49871_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/bc4df5149897/41467_2024_49871_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/4943d3bc534a/41467_2024_49871_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/2eff491dbe82/41467_2024_49871_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4ba/11239676/847eaf2f29a0/41467_2024_49871_Fig8_HTML.jpg

相似文献

1
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.转录共抑制因子 Runx1t1 对于 MYCN 驱动的神经母细胞瘤肿瘤发生是必需的。
Nat Commun. 2024 Jul 11;15(1):5585. doi: 10.1038/s41467-024-49871-0.
2
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.高尔基定位环指蛋白 121 对于 MYCN 驱动的神经母细胞瘤肿瘤发生是必需的。
Commun Biol. 2024 Oct 14;7(1):1322. doi: 10.1038/s42003-024-06899-8.
3
Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.神经母细胞瘤发生中 miRNA-mRNA 相互作用的网络建模鉴定 miR-204 为 MYCN 的直接抑制剂。
Cancer Res. 2018 Jun 15;78(12):3122-3134. doi: 10.1158/0008-5472.CAN-17-3034. Epub 2018 Apr 2.
4
SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.SMARCE1 通过协助 MYCN 介导的转录激活促进神经母细胞瘤发生。
Oncogene. 2022 Sep;41(37):4295-4306. doi: 10.1038/s41388-022-02428-1. Epub 2022 Aug 17.
5
The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.PLAGL2/MYCN/miR-506-3p 相互作用调控神经母细胞瘤细胞命运并与神经母细胞瘤进展相关。
J Exp Clin Cancer Res. 2020 Feb 22;39(1):41. doi: 10.1186/s13046-020-1531-2.
6
LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.赖氨酸特异性去甲基化酶1(LSD1)通过使转移抑制因子NDRG1基因沉默,介导MYCN对上皮-间质转化的调控。
Oncotarget. 2017 Jan 17;8(3):3854-3869. doi: 10.18632/oncotarget.12924.
7
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.在肿瘤起始时的有丝分裂调控失调为 MYCN 驱动的神经母细胞瘤创造了联合抗有丝分裂和促凋亡药物治疗的潜在弱点。
Int J Mol Sci. 2023 Oct 25;24(21):15571. doi: 10.3390/ijms242115571.
8
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.MYCN 通过与转录因子 AP4 建立调控回路来促进神经母细胞瘤的恶性发展。
Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.
9
MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.MYCN 和 PRC1 通过 ELOVL2 协同抑制神经母细胞瘤中二十二碳六烯酸的合成。
J Exp Clin Cancer Res. 2019 Dec 19;38(1):498. doi: 10.1186/s13046-019-1492-5.
10
HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.HAND2 辅助 MYCN 增强子侵袭以调节去甲肾上腺素能神经母细胞瘤表型。
Cancer Res. 2023 Mar 2;83(5):686-699. doi: 10.1158/0008-5472.CAN-22-2042.

引用本文的文献

1
Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.纵向单细胞分析揭示RUNX1T1是治疗诱导的神经内分泌转分化的早期驱动因素。
bioRxiv. 2025 May 18:2025.05.14.653660. doi: 10.1101/2025.05.14.653660.
2
An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma.增殖与分化之间的失衡是微小RNA缺陷型松果体母细胞瘤发生发展的基础。
Genes Dev. 2025 Apr 16. doi: 10.1101/gad.352485.124.
3
Molecular principles underlying aggressive cancers.

本文引用的文献

1
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner.MYCMI-7:一种小分子 MYC 结合化合物,可抑制 MYC: MAX 相互作用,并以依赖 MYC 的方式抑制肿瘤生长。
Cancer Res Commun. 2022 Mar 31;2(3):182-201. doi: 10.1158/2767-9764.CRC-21-0019. eCollection 2022 Mar.
2
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma.神经母细胞瘤小鼠模型病理评估入门。
Curr Protoc. 2021 Nov;1(11):e310. doi: 10.1002/cpz1.310.
3
The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.
侵袭性癌症的分子原理。
Signal Transduct Target Ther. 2025 Feb 17;10(1):42. doi: 10.1038/s41392-025-02129-7.
4
An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma.增殖与分化之间的失衡是微小RNA缺陷型松果体母细胞瘤发生发展的基础。
bioRxiv. 2024 Oct 22:2024.04.23.590638. doi: 10.1101/2024.04.23.590638.
MYC 癌基因——癌症生长和免疫逃逸的总指挥。
Nat Rev Clin Oncol. 2022 Jan;19(1):23-36. doi: 10.1038/s41571-021-00549-2. Epub 2021 Sep 10.
4
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.修正的神经母细胞瘤风险分类系统:来自儿童肿瘤协作组的报告。
J Clin Oncol. 2021 Oct 10;39(29):3229-3241. doi: 10.1200/JCO.21.00278. Epub 2021 Jul 28.
5
MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.MYC 癌基因与肿瘤免疫抑制有关,靶向 Myc 可诱导肿瘤细胞免疫原性,用于治疗性全细胞疫苗接种。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001388.
6
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.EZH2 抑制可降低神经母细胞瘤的增殖和体内肿瘤生长。
PLoS One. 2021 Mar 9;16(3):e0246244. doi: 10.1371/journal.pone.0246244. eCollection 2021.
7
Targeting in Pediatric and Adult Cancers.儿科和成人癌症中的靶向治疗
Front Oncol. 2021 Feb 8;10:623679. doi: 10.3389/fonc.2020.623679. eCollection 2020.
8
The RUNX1/RUNX1T1 network: translating insights into therapeutic options.RUNX1/RUNX1T1 网络:将见解转化为治疗选择。
Exp Hematol. 2021 Feb;94:1-10. doi: 10.1016/j.exphem.2020.11.005. Epub 2020 Nov 17.
9
Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer.鉴定 RUNX1T1 为小细胞肺癌中的一个潜在表观遗传修饰物。
Mol Oncol. 2021 Jan;15(1):195-209. doi: 10.1002/1878-0261.12829. Epub 2020 Nov 27.
10
drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity.驱动小细胞肺癌的化疗耐药性,而 USP7 抑制可以恢复化疗敏感性。
Genes Dev. 2020 Sep 1;34(17-18):1210-1226. doi: 10.1101/gad.340133.120. Epub 2020 Aug 20.